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In a recent article in Genome Research [1], Thompson and 
colleagues  present  a  development  of  a  next-genera  tion 
sequencing technology - the HeliScope sequencer - that 
enabled  them  to  detect  mutations  in  the  human  breast 
cancer 1 (BRCA1) gene, as a model of a clinical diag  nostic 
protocol. Their technique is accurate and requires limited 
sample preparation before sequencing. It therefore holds 
great  promise  for  overcoming  the  emerging  problem  in 
clinical genetics of target overload: the presence of a large 
number of gene mutations of clinical relevance in a single 
disease entity. In no field is this challenge more apparent 
than in the genomics of cancer.
The clinical application of next-generation 
sequencing
The past few years have seen an unprecedented deluge of 
data on the genes mutated in cancer and other diseases. 
So  far,  the  sequences  of  over  50  individual  cancer 
genomes have been published and this number is set to 
increase  exponentially.  The  advent  of  next-generation 
technologies (such as the Roche 454 GS FLX+, llumina 
Hiseq 2000, Applied Biosystems SOLID and HeliScope 
single-molecule  sequencer  machines),  which  allow  a 
human genome to be sequenced in a single week-long 
run, has led to a large shift in our understanding of the 
mutations that drive cancers [2]. For the clinician, muta-
tions in cancer can have relevance for diagnosis, prog-
nosis and treatment choice. However, it is now apparent 
that  these  clinically  relevant  mutations  will  be  both 
numerous  and  found  at  low  prevalence  in  individual 
cancer  types.  In  particular,  for  the  majority  of  cancers 
there will be no single ‘magic bullet’ targeted therapy. The 
breakpoint  cluster  region-Abelson  murine  leukemia 
homolog (BCR-ABL) fusion kinase, which is character-
istic of chronic myeloid leukemia, is the exception not 
the  rule  when  it  comes  to  druggable  cancer  genes;  it 
seems, instead, that multiple drug targets will be mutated 
at low frequency throughout common cancers [3]. This 
target overload is not restricted to the management of 
cancers and is also seen with monogenic disorders, for 
example, mental retardation and hereditary cancer pre-
disposition [4].
It  is  therefore  necessary  to  screen  numerous  genetic 
loci to decide on the best course of clinical management 
for an individual patient and this must be done in a rapid 
and  cost-effective  manner.  The  current  technology  for 
searching for mutations is to amplify a region of interest - 
in multiple fragments of a few hundred base pairs each in 
separate PCR reactions - then sequence the products by 
standard Sanger chain terminator sequencing. Although 
highly  accurate  for  the  detection  of  single-nucleotide 
variants and small insertions or deletions, this approach 
is expensive, labor intensive and unable to detect large-
scale  insertions  or  deletions.  Furthermore,  in  tumor 
samples, mutations may be missed. This is because Sanger 
sequencing can reliably detect mutant alleles only when 
they are present in more than about 20% of the relevant 
DNA, and this will not be the case, for example, for a 
heterozygous  mutation  in  a  tumor  contaminated  with 
60% normal DNA, a scenario that is not uncommon [5].
Targeted true single-molecule sequencing
Thompson and colleagues [1] have used a next-generation 
true  single-molecule  sequencing  (tSMS)  system,  the 
HeliScope sequencer, to profile the mutational pattern of 
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© 2011 BioMed Central Ltdthe human cancer gene BRCA1. Germline mutations in 
the  genes  BRCA1  and  BRCA2  are  associated  with 
dramati  cally increased rates of breast and ovarian cancers 
and contribute to about 10% of all breast cancer cases [6]. 
In  addition,  poly-ADP  ribose  polymerase  inhibitors,  a 
recently  developed  family  of  pharmaceutical  agents, 
seem to show selective toxicity for cancers with muta-
tions  in  the  BRCA  genes.  Cost-effective  sequencing  of 
these genes is therefore a highly desirable clinical tool for 
the management of breast cancer patients and those with 
strong family histories of the disease.
The technology used is a development of the HeliScope 
tSMS  platform  [1].  In  the  standard  HeliScope  protocol, 
DNA is fragmented and poly(A) adaptors are added to the 
ends of fragments. They are then captured on a glass slide 
coated with covalently bound poly(dT) oligo  nucleo  tides, 
and  sequenced  [7].  Thompson  et  al.  [1]  were  able  to 
dispense with the initial sample preparation steps (addi-
tion of poly(A) adaptors and 3’ blocking - performed to 
prevent extension of the 3’ end of bound poly(A)-tagged 
DNA molecules) and instead directly captured only the 
fragments of DNA belonging to the BRCA1 locus, using 
oligonucleotides  that  match  sequences  in  the  BRCA1 
region  (Figure  1).  This  targeted  capture  approach  was 
highly success  ful. Approximately 20% of the sequenced 
reads  mapped  to  BRCA1,  which  equates  to  about 
100,000-fold enrich  ment of the target sequence. As the 
length  of  sequence  that  can  be  read  in  this  system  is 
limited,  oligonucleotides  were  designed  at  20-30  base 
pair  intervals  throughout  the  coding  sequence  of  the 
gene,  to  ensure  complete  coverage.  Importantly,  the 
authors [1] were able to obtain sequencing results from 
as little as 100 ng of input material - thus showing that 
the technology could be used with samples collected as 
diagnostic biopsies.
This approach [1] has several advantages over the more 
traditional  Sanger  sequencing  commonly  used  for  the 
detection of mutations. Firstly, there is little required in 
the way of sample preparation - only sonication of the 
DNA, and in the case of archival formalin-fixed material 
it is possible that even this step could be dispensed with - 
therefore reducing cost, turn-around time and the risk of 
errors  in  sample  handling.  Secondly,  unlike  Sanger 
sequenc  ing, the HeliScope system allows the detection of 
large deletions, by determining the number of fragments 
of  DNA  that  are  present  from  a  specific  location;  a 
decreased number of fragments from a region suggests a 
loss  of  genetic  material.  Finally,  the  HeliScope  system 
directly sequences individual molecules rather than - as 
with  Sanger  sequencing  -  examining  the  average 
sequence  of  many  millions  of  DNA  molecules.  This 
should provide increased sensitivity for the detection of 
low  prevalence  mutations,  an  essential  feature  in  the 
sequencing of a heterogeneous cancer sample.
The present technology [1] is an advance over recently 
presented techniques for analyzing the mutational status 
of  target  genes  using  next-generation  sequencing 
instruments [8,9]. With the advent of more competitively 
priced next-generation sequencing machines, which can 
provide  sequence  data  in  a  matter  of  hours,  not  days 
(such  as  Life  Technologies’  Ion-torrent  and  Illumina’s 
Miseq), it is feasible that such approaches could be used 
routinely in the clinical setting. However, the instruments 
involved still require the selective amplification of target 
DNA  and  the  relatively  complex  preparation  of  this 
material for sequencing. Thus, although they take advan-
tage  of  the  exceptionally  cheap  per-base  cost  of  next-
generation  sequencing,  competing  techniques  are  still 
limited by its flaws: high complexity and slow turnaround 
time.  Genotyping  by  mass  spectrometry  has  also  been 
Figure 1. Outline of the tSMS gene capture approach. Tumor 
material can be collected and (a) snap frozen to preserve intact 
DNA and RNA or (b) fixed in formalin then embedded in paraffin for 
section and histopathological review. Following (c) DNA extraction, 
(d) the DNA is broken by sonication to approximately 200 bp 
fragments. Green, sequences from the BRCA1 region; black, other 
regions. Formalin fixed material provides fragmented DNA, removing 
the need for a sonication step. (e) DNA fragments are hybridized to 
the flow cell, which is covered with oligonucleotides with sequence 
complementary to the region corresponding to the BRCA1 gene. 
BRCA1 sequences are therefore enriched on the flow cell. (f) Each 
individual molecule of DNA is then sequenced simultaneously by 
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This approach, although sensitive, is limited, in that it is 
capable  of  detecting  only  known  mutations  and  will 
therefore miss novel gene lesions.
The future of gene sequencing in the clinic
For the foreseeable future, the high cost and complexity 
of  data  analysis  will  limit  the  application  of  whole-
genome sequencing for the detection of mutations in a 
clinical setting. Targeted resequencing of areas of interest 
will  therefore  remain  key  to  determining  mutational 
status. The method published by Thompson et al. [1] is a 
stride  forward  in  putting  this  into  practice.  Although 
currently only a single gene is screened, there is clearly 
scope  for  the  creation  of  multi-gene  capture  arrays, 
allowing large numbers of loci to be analyzed rapidly and 
cost-effectively with low DNA input requirements. In its 
simplicity, this approach provides an opportunity to truly 
begin  integrating  the  vast  quantity  of  genomic  data 
generated in this next-generation era with clinical practice.
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